AstraZeneca, the British-Swedish pharmaceutical company that developed one of the world’s leading Covid-19 vaccines contributed to earnings per share in the third quarter (3Q) with a profit of $ 1.05 on sales of the vaccine as of Friday.
The vaccine maker recorded a 1 sen increase in earnings per share in Q3 this year and is expected to maintain the momentum of the ‘moderate profit’ movement in the future.
The company said profits in the fourth quarter (4Q) will cover costs related to the cocktail antibodies they are working on to prevent and treat Covid-19, as it is on track that has been set this year.
The company's total revenue jumped 47% to US $ 9.74 billion for the 3 months to September while core revenue generated US $ 1.08 per share.
According to data released by Refinitiv IBES, it expects the company’s profit to reach $ 1.28 per share on sales of $ 9.4 billion.
Meanwhile, their closest competitor Pfizer, expects sales in 2021 and 2022 to generate $ 65 billion in total while Moderna predicts sales in 2021 to reach $ 5 billion.
